Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Growth 2020-2025
According to this study, over the next five years the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market by product type, application, key manufacturers and key regions and countries.
This study specially analyses the impact of Covid-19 outbreak on the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, covering the supply chain analysis, impact assessment to the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size growth rate in several scenarios, and the measures to be undertaken by Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs companies in response to the COVID-19 epidemic.
Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Eluxadoline
Alosetron
Rifaximin
Loperamide
Diphenoxylate + Atropine
Dicyclomine and Hyoscyamine
Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Hospitals
Clinics
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Astellas Pharmaceuticals
Actavis
GlaxoSmithKline
Salix Pharmaceuticals Ltd
Pfizer
AstraZenenca
...
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market by identifying its various subsegments.
Focuses on the key global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2015-2025
2.1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption CAGR by Region
2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Type
2.2.1 Eluxadoline
2.2.2 Alosetron
2.2.3 Rifaximin
2.2.4 Loperamide
2.2.5 Diphenoxylate + Atropine
2.2.6 Dicyclomine and Hyoscyamine
2.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type
2.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020)
2.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Type (2015-2020)
2.3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Type (2015-2020)
2.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Others
2.5 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application
2.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020)
2.5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value and Market Share by Type (2015-2020)
2.5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Type (2015-2020)
3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Company
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company
3.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company (2018-2020)
3.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company (2018-2020)
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company
3.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2018-2020)
3.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company (2018-2020)
3.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Company
3.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Regions
4.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Regions
4.2 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth
4.3 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth
4.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth
4.5 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth
5 Americas
5.1 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries
5.1.1 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries (2015-2020)
5.1.2 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Countries (2015-2020)
5.2 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type
5.3 Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries
6 APAC
6.1 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Regions
6.1.1 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Regions (2015-2020)
6.1.2 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Regions (2015-2020)
6.2 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type
6.3 APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions
7 Europe
7.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Countries
7.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries (2015-2020)
7.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Countries (2015-2020)
7.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type
7.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries
8 Middle East & Africa
8.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Countries
8.1.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Countries (2015-2020)
8.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type
8.3 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends
10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors
10.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customer
11 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast
11.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast (2021-2025)
11.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Regions
11.2.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Regions (2021-2025)
11.2.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Type
11.8 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Forecast by Application
12 Key Players Analysis
12.1 Astellas Pharmaceuticals
12.1.1 Company Information
12.1.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
12.1.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Astellas Pharmaceuticals Latest Developments
12.2 Actavis
12.2.1 Company Information
12.2.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
12.2.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Actavis Latest Developments
12.3 GlaxoSmithKline
12.3.1 Company Information
12.3.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
12.3.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 GlaxoSmithKline Latest Developments
12.4 Salix Pharmaceuticals Ltd
12.4.1 Company Information
12.4.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
12.4.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Salix Pharmaceuticals Ltd Latest Developments
12.5 Pfizer
12.5.1 Company Information
12.5.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
12.5.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Pfizer Latest Developments
12.6 AstraZenenca
12.6.1 Company Information
12.6.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product Offered
12.6.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 AstraZenenca Latest Developments
...
13 Research Findings and Conclusion
Tables and Figures
List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of Eluxadoline
Table 5. Major Players of Alosetron
Table 6. Major Players of Rifaximin
Table 7. Major Players of Loperamide
Table 8. Major Players of Diphenoxylate + Atropine
Table 9. Major Players of Dicyclomine and Hyoscyamine
Table 10. Global Consumption Sales by Type (2015-2020)
Table 11. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020)
Table 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2015-2020) ($ million)
Table 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Type (2015-2020) ($ Millions)
Table 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Type (2015-2020)
Table 15. Global Consumption Sales by Application (2015-2020)
Table 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application (2015-2020)
Table 17. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Application (2015-2020)
Table 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Application (2015-2020)
Table 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Application (2015-2020)
Table 20. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Company (2017-2019) (K MT)
Table 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company (2017-2019)
Table 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Company (2017-2019) ($ Millions)
Table 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company (2017-2019)
Table 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Company (2017-2019)
Table 25. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base Distribution and Sales Area by Manufacturers
Table 26. Players Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Products Offered
Table 27. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Regions 2015-2020 (K MT)
Table 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Regions 2015-2020
Table 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Regions 2015-2020 ($ Millions)
Table 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Regions 2015-2020
Table 32. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries (2015-2020) (K MT)
Table 33. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries (2015-2020)
Table 34. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Countries (2015-2020) ($ Millions)
Table 35. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Countries (2015-2020)
Table 36. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type (2015-2020) (K MT)
Table 37. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020)
Table 38. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application (2015-2020) (K MT)
Table 39. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application (2015-2020)
Table 40. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries (2015-2020) (K MT)
Table 41. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries (2015-2020)
Table 42. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Regions (2015-2020) ($ Millions)
Table 43. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Regions (2015-2020)
Table 44. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type (2015-2020) (K MT)
Table 45. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020)
Table 46. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application (2015-2020) (K MT)
Table 47. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application (2015-2020)
Table 48. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries (2015-2020) (K MT)
Table 49. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries (2015-2020)
Table 50. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Countries (2015-2020) ($ Millions)
Table 51. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Countries (2015-2020)
Table 52. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type (2015-2020) (K MT)
Table 53. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020)
Table 54. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application (2015-2020) (K MT)
Table 55. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application (2015-2020)
Table 56. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Countries (2015-2020) (K MT)
Table 57. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries (2015-2020)
Table 58. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value by Countries (2015-2020) ($ Millions)
Table 59. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Countries (2015-2020)
Table 60. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Type (2015-2020) (K MT)
Table 61. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020)
Table 62. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption by Application (2015-2020) (K MT)
Table 63. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application (2015-2020)
Table 64. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Distributors List
Table 65. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Customer List
Table 66. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Countries (2021-2025) (K MT)
Table 67. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Forecast by Regions
Table 68. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Forecast by Countries (2021-2025) ($ Millions)
Table 69. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share Forecast by Regions
Table 70. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Type (2021-2025) (K MT)
Table 71. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share Forecast by Type (2021-2025)
Table 72. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Forecast by Type (2021-2025) ($ Millions)
Table 73. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share Forecast by Type (2021-2025)
Table 74. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Forecast by Application (2021-2025) (K MT)
Table 75. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share Forecast by Application (2021-2025)
Table 76. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Forecast by Application (2021-2025) ($ Millions)
Table 77. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share Forecast by Application (2021-2025)
Table 78. Astellas Pharmaceuticals Product Offered
Table 79. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 80. Astellas Pharmaceuticals Main Business
Table 81. Astellas Pharmaceuticals Latest Developments
Table 82. Astellas Pharmaceuticals Basic Information, Company Total Revenue (in $ million), Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Actavis Product Offered
Table 84. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 85. Actavis Main Business
Table 86. Actavis Latest Developments
Table 87. Actavis Basic Information, Company Total Revenue (in $ million), Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. GlaxoSmithKline Product Offered
Table 89. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 90. GlaxoSmithKline Main Business
Table 91. GlaxoSmithKline Latest Developments
Table 92. GlaxoSmithKline Basic Information, Company Total Revenue (in $ million), Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. Salix Pharmaceuticals Ltd Product Offered
Table 94. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 95. Salix Pharmaceuticals Ltd Main Business
Table 96. Salix Pharmaceuticals Ltd Latest Developments
Table 97. Salix Pharmaceuticals Ltd Basic Information, Company Total Revenue (in $ million), Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Pfizer Product Offered
Table 99. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 100. Pfizer Main Business
Table 101. Pfizer Latest Developments
Table 102. Pfizer Basic Information, Company Total Revenue (in $ million), Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. AstraZenenca Product Offered
Table 104. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2020E)
Table 105. AstraZenenca Main Business
Table 106. AstraZenenca Latest Developments
Table 107. AstraZenenca Basic Information, Company Total Revenue (in $ million), Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturing Base, Sales Area and Its Competitors
List of Figures
Figure 1. Picture of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs
Figure 2. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth Rate 2015-2025 (K MT)
Figure 5. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Eluxadoline
Figure 7. Product Picture of Alosetron
Figure 8. Product Picture of Rifaximin
Figure 9. Product Picture of Loperamide
Figure 10. Product Picture of Diphenoxylate + Atropine
Figure 11. Product Picture of Dicyclomine and Hyoscyamine
Figure 12. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type (2015-2020)
Figure 13. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Type (2015-2020)
Figure 14. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumed in Hospitals
Figure 15. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Hospitals (2015-2020) (K MT)
Figure 16. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Hospitals (2015-2020) ($ Millions)
Figure 17. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumed in Clinics
Figure 18. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Clinics (2015-2020) (K MT)
Figure 19. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Clinics (2015-2020) ($ Millions)
Figure 20. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumed in Others
Figure 21. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Others (2015-2020) (K MT)
Figure 22. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market: Others (2015-2020) ($ Millions)
Figure 23. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application (2015-2020)
Figure 24. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Application (2015-2020)
Figure 25. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company in 2017
Figure 26. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Company in 2019
Figure 27. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company in 2017
Figure 28. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Company in 2019
Figure 29. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sale Price by Company in 2019
Figure 30. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Regions 2015-2020
Figure 31. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Regions 2015-2020
Figure 32. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2015-2020 (K MT)
Figure 33. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2015-2020 ($ Millions)
Figure 34. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2015-2020 (K MT)
Figure 35. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2015-2020 ($ Millions)
Figure 36. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2015-2020 (K MT)
Figure 37. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2015-2020 ($ Millions)
Figure 38. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2015-2020 (K MT)
Figure 39. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2015-2020 ($ Millions)
Figure 40. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries in 2019
Figure 41. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Countries in 2019
Figure 42. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type in 2019
Figure 43. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application in 2019
Figure 44. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 45. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 46. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 47. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 48. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 49. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 50. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries in 2019
Figure 51. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Regions in 2019
Figure 52. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type in 2019
Figure 53. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application in 2019
Figure 54. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 55. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 56. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 57. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 58. Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 59. Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 60. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 61. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 62. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 63. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 64. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 65. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 66. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries in 2019
Figure 67. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Countries in 2019
Figure 68. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type in 2019
Figure 69. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application in 2019
Figure 70. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 71. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 72. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 73. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 74. UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 75. UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 76. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 77. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 78. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 79. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 80. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Countries in 2019
Figure 81. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Market Share by Countries in 2019
Figure 82. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Type in 2019
Figure 83. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Market Share by Application in 2019
Figure 84. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 85. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 86. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 87. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 88. Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 89. Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 90. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 91. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 92. GCC Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth 2015-2020 (K MT)
Figure 93. GCC Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth 2015-2020 ($ Millions)
Figure 94. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption Growth Rate Forecast (2021-2025) (K MT)
Figure 95. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 96. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 97. Americas Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 98. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 99. APAC Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 100. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 101. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 102. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 103. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 104. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 105. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 106. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 107. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 108. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 109. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 110. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 111. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 112. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 113. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 114. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 115. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 116. Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 117. Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 118. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 119. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 120. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 121. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 122. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 123. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 124. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 125. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 126. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 127. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 128. UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 129. UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 130. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 131. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 132. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 133. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 134. Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 135. Spain Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 136. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 137. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 138. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 139. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 140. Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 141. Israel Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 142. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 143. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 144. GCC Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Consumption 2021-2025 (K MT)
Figure 145. GCC Countries Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Value 2021-2025 ($ Millions)
Figure 146. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share (2018-2020)
Figure 147. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share (2018-2020)
Figure 148. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share (2018-2020)
Figure 149. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share (2018-2020)
Figure 150. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share (2018-2020)
Figure 151. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share (2018-2020)
Reason to Buy
- Current and future of Pharma & Healthcare Market outlook in the developed and emerging markets
- Highlights key business priorities in order to assist companies to realign their business strategies
- The segment that is expected to dominate the Pharma & Healthcare Market
- Regions that are expected to witness the fastest growth during the forecast period
- Identify the latest developments, Pharma & Healthcare Market shares, and strategies employed by the major market players
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the global Pharma & Healthcare Market
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets